Abstract
The management of heparin-induced thrombocytopenia (HIT) in pregnancy represents a medical challenge. The advent of new antithrombotic agents that do not cross-react with platelet factor 4 and heparin antibodies represents an important progress, and they are of utmost interest in special situations such as early pregnancy, a situation where the teratogenicity of warfarin precludes its use.Figures & Tables
Article Information
Published
2006-01-01
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
Article Usage
Online Views
559
PDF Downloads
261
No Data